Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Dina Caceres
    RCphone +1 (305) 2437561

    IRB: 20170529

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:

    IRB: 20200056

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201131 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:

    IRB: 20201131

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Multiple
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
    Eligibility Criteria - NCT04530981 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201132 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:

    IRB: 20201132

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Soft Tissue
    Sponsor: Tracon

    Enrolling Sites:

    Sylvester
    Title:

    A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy
    Eligibility Criteria - NCT04480502 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211062 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:

    IRB: 20211062

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Multiple
    Sponsor: Sumitomo Dainippon Pharma Oncology

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients With Advanced Solid Tumors
    Eligibility Criteria - NCT03604783 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230466 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:

    IRB: 20230466

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bones and Joints,Soft Tissue
    Sponsor: Alliance

    Enrolling Sites:

    Deerfield
    Plantation
    Sylvester
    Title:

    A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy
    Eligibility Criteria - NCT05633381 *This information has been extracted from " www.clinicaltrials.gov"

  • 20160793 - Dhir Aditi

  • Investigator:
    Aditi Dhir
    RCname Email

    		Coordinator:
    RCemailImg Eva Pavicic
    RCphone +1 (305) 2437846

    IRB: 20160793

    		SDG: Pediatric Cancer
    Disease Site(s):

    Soft Tissue
    Sponsor: Moffitt Cancer Center

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
    Eligibility Criteria - NCT02945800 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221175 - Jonczak Emily

  • Investigator:
    Emily Jonczak
    RCname Email

    		Coordinator:

    IRB: 20221175

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bones and Joints
    Sponsor: AmMax Bio. Inc

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra articular AMB-05X Injections in Subjects with Tenosynovial Giant Cell Tumor
    Eligibility Criteria - NCT05349643 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191009 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:

    IRB: 20191009

    		SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Bones and Joints,Lip, Oral Cavity and Pharynx
    Sponsor: HOOKIPA PHARMA

    Enrolling Sites:

    Sylvester
    Title:

    A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers
    Eligibility Criteria - NCT04180215 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Rodriguez, Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone +1 (786) 5828551

    IRB: 20180802

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin,Other Skin
    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester
    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201368 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20201368

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Multiple
    Sponsor: SCCC

    Enrolling Sites:

    Plantation
    Sylvester
    Title:

    ctDNA-Guided Sunitinib And Regorafenib Therapy for Gastrointestinal Stromal Tumor (GIST)
    Eligibility Criteria - NCT05366816 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201373 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20201373

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Hodgkin Lymphoma,Lip, Oral Cavity and Pharynx,Lung,Melanoma, skin,Soft Tissue
    Sponsor: Agenus

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
    Eligibility Criteria - NCT03860272 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211168 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20211168

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Colon,Esophagus,Small Intestine,Soft Tissue,Stomach
    Sponsor: Theseus Pharmaceuticals

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti- Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
    Eligibility Criteria - NCT05160168 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211225 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:
    RCemailImg Ravipal Luthra
    RCphone +1 (305) 2430933

    IRB: 20211225

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Multiple
    Sponsor: Cogent Biosciences

    Enrolling Sites:

    Sylvester
    Title:

    (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS
    Eligibility Criteria - NCT05208047 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220946 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20220946

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bones and Joints
    Sponsor: ADVENCHEN LABORATORIES

    Enrolling Sites:

    Sylvester
    Title:

    An Open Label Post-Trial Access (PTA) of Catequentinib (AL3818, Anlotinib) Hydrochloride Mono or in Combination Therapies in Patients Who Have Completed an Advenchen Sponsored Oncology Study with AL3818 (A Compassionate Use Trial)
    Eligibility Criteria - NCT05612191 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220980 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20220980

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Multiple
    Sponsor: IDRX

    Enrolling Sites:

    Sylvester
    Title:

    A First-In-Human (FIH) Study Of Idrx-42 In Participants With Metastatic And/Or Unresectable Gastrointestinal Stromal Tumors (GIST)
    Eligibility Criteria - NCT05489237 *This information has been extracted from " www.clinicaltrials.gov"